Your Patients Need Amikacin — Here's How to Help Them Find It

When you prescribe Amikacin for a serious bacterial infection, you expect it to be available. But ongoing shortages of this critical aminoglycoside antibiotic mean that patients and their care teams increasingly face the challenge of sourcing it. As a provider, you're uniquely positioned to help bridge this gap.

This guide offers practical strategies for helping your patients locate Amikacin, navigate shortages, and access alternatives when necessary.

Current Amikacin Availability

As of 2026, Amikacin injection (250 mg/mL) remains on the ASHP Drug Shortage Database. The key supply facts:

• Hikma (West-Ward): 2 mL and 4 mL vials on long-term back order, no estimated release date
• Other manufacturers: Intermittent supply of select presentations
• Arikayce: The branded liposomal inhalation form (Insmed) is a separate product indicated only for MAC lung disease — not interchangeable with injectable Amikacin

Supply varies by region, distributor, and vial size. Hospital systems with GPO contracts may have allocation access that outpatient facilities do not.

Why Patients Can't Find Amikacin

Several factors make Amikacin particularly difficult for patients to source on their own:

• It's an injectable: Unlike oral medications, Amikacin requires IV or IM administration, meaning it's not stocked at most retail pharmacies
• Shortage dynamics: With limited manufacturers and ongoing back orders, even specialty pharmacies may be unable to obtain it consistently
• Fragmented information: Patients have no easy way to check which suppliers have stock — they're left calling pharmacy after pharmacy
• Outpatient IV therapy complexity: Patients receiving home infusion therapy rely on their infusion pharmacy for sourcing, adding another layer of potential delay

What Providers Can Do: 5 Practical Steps

Step 1: Proactively Check Availability Before Prescribing

Before finalizing an Amikacin prescription for outpatient therapy, verify current availability with the patient's specialty or home infusion pharmacy. If the drug isn't available, you can adjust the treatment plan immediately rather than sending the patient on a futile search.

Use Medfinder for Providers to check real-time stock across pharmacies and suppliers.

Step 2: Leverage Institutional Pharmacy Resources

If your institution stocks Amikacin, coordinate with your pharmacy department to:

• Determine current inventory levels and expected restock dates
• Request manufacturer allocations through your GPO
• Explore 503B compounding outsourcing facilities for compounded Amikacin during the declared shortage

Step 3: Connect Patients With Specialty Pharmacies

Provide patients with specific referrals to specialty pharmacies or home infusion companies that you know handle injectable antibiotics. A warm handoff — where your office contacts the pharmacy directly — is more effective than asking the patient to navigate this alone.

Step 4: Write Flexible Prescriptions When Clinically Appropriate

If culture and sensitivity data support it, consider:

• Writing for an alternative aminoglycoside (Gentamicin or Tobramycin) as a backup
• Specifying flexibility on vial size (e.g., accepting 4 mL vials if 2 mL vials are unavailable, or vice versa)
• Including notes for the pharmacist about acceptable substitutions to avoid callbacks and delays

Step 5: Direct Patients to Availability Tools

Empower patients with the tools to help themselves. Recommend Medfinder so they can search for Amikacin availability in real time. You can also direct them to our patient-facing resources:

• How to find Amikacin in stock near you
• Amikacin shortage update for 2026
• How to save money on Amikacin

Alternatives to Consider

When Amikacin cannot be sourced, alternative selection should be guided by culture and sensitivity data, infection site, and patient-specific factors:

• Gentamicin: Most widely available aminoglycoside; first-line alternative when susceptibility is confirmed
• Tobramycin: Preferred for Pseudomonas infections; available as injectable and inhaled formulations
• Plazomicin (Zemdri): Active against many aminoglycoside-resistant organisms; FDA-approved for cUTI/pyelonephritis; may require prior authorization
• Non-aminoglycoside options: Carbapenems, Ceftazidime-Avibactam, or polymyxins depending on resistance profile

For detailed alternative information, see our guide to Amikacin alternatives.

Workflow Tips for Shortage Management

Incorporate these practices into your clinical workflow to minimize disruption from ongoing Amikacin shortages:

• Add a shortage check to your prescribing workflow for all aminoglycosides — verify availability before the patient leaves the office
• Maintain a list of specialty and home infusion pharmacies in your area that handle injectable antibiotics
• Establish relationships with 1–2 compounding pharmacies that can produce sterile injectables during shortages
• Communicate proactively with patients about potential supply issues and your contingency plan
• Bookmark Medfinder for Providers and the ASHP Drug Shortage Database for quick reference
• Document alternative protocols in your institutional formulary so the entire team can respond quickly when a shortage affects a prescribed drug

Final Thoughts

Amikacin shortages put providers in a difficult position — you know the drug is the right choice, but it may not be available. By incorporating availability checks into your prescribing workflow, maintaining specialty pharmacy relationships, and using tools like Medfinder, you can reduce the burden on your patients and keep treatment on track.

For more provider resources, see our provider shortage briefing, guide to helping patients save money on Amikacin, and patient-facing articles on Amikacin side effects and drug interactions.